Xcout Intelペプチドリーム
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.
Subscribe to see ペプチドリーム’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ペプチドリーム at a glance
ペプチドリーム is a biotech company headquartered in Kawasaki, Japan. It is publicly listed (4587) with a market capitalisation of $809.1M.
ペプチドリーム competitors
A few of ペプチドリーム's closest competitors — see the full list of competitors and alternatives →
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Parabilis Medicines is a biopharmaceutical company that develops ultra-tunable peptide therapeutics utilizing its proprietary Helicon platform. The company focuses on creating novel medicines to target historically undruggable conditions, primarily addressing cancer and other serious diseases with critical medical needs.
Perseus Proteomics Inc. is a Japanese biotechnology company focused on antibody drug discovery and research support. The firm develops novel therapeutic antibody drugs for cancer and other diseases utilizing its proprietary antibody technologies.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company headquartered at the Pacific Research Center in Newark, California, focused on peptide drug discovery.
Peptilogics, Inc. is a biotechnology company founded in 2013 and headquartered in Pittsburgh, Pennsylvania. The company utilizes advanced computational and biological approaches to discover and develop novel peptide therapeutics.
Get ペプチドリーム's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ペプチドリーム in Xcout Intel
- The full competitor set, tracking, exports and API access